Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Oxybutynin (02350238). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

OXYBUTYNIN CHLORIDE

Form:

6 of 6 products shown

4 general benefit · 2 not a benefit

Other products in the same Health Canada class (G04BD) — coverage varies; not interchangeable

  • Flavoxate (Urispas): not a benefit

PMS-Oxybutynin · DIN 02223376 · 1mg/mL · oral liquid

General benefitMarketed · checked 2026-09-18
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Oxybutynin · DIN 02223376 Manufacturer: Pharmascience Inc.; listing date 1998-12-31 Health Canada: Marketed since 1996-09-04 · brand PMS-OXYBUTYNIN · ATC G04BD04 OXYBUTYNIN · form Syrup · route Oral · ingredients OXYBUTYNIN CHLORIDE 5 MG/5ML · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Oxybutynin: Formulary list price $0.1249/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1249 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43358 · Verify on the e-Formulary ↗ (DIN 02223376)

Source record
DIN 02223376: PMS-Oxybutynin Raw flags: sec3=Y Item: 120800034; group id 209; item number 0379; lccId None; manufacturer id PMS Source form: O/L; strength: 1mg/mL Recorded listing: General benefit Source prices (unrounded): $0.1249; ministry $0.1249 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02223376 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43358
Interchangeable products
Ditropan · DIN 01924753 · not recorded
Shortage status: resolved shortage (ended 2025-03-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02223376
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Oxybutynin · DIN 02163543 · 5mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Oxybutynin · DIN 02163543 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 2022-01-25 · brand APO-OXYBUTYNIN · ATC G04BD04 OXYBUTYNIN · form Tablet · route Oral · ingredients OXYBUTYNIN CHLORIDE 5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Oxybutynin: Formulary list price $0.0986/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0986 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18355 · Verify on the e-Formulary ↗ (DIN 02163543)

Source record
DIN 02163543: Apo-Oxybutynin Raw flags: sec3=Y Item: 120800033; group id 209; item number 0380; lccId None; manufacturer id APX Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.0986; ministry $0.0986 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02163543 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18355
Interchangeable products
Ditropan · DIN 01924761 · not recorded Novo-Oxybutynin · DIN 02230394 · $0.0986 PMS-Oxybutynin · DIN 02240550 · $0.0986
Shortage status: shortage reported ended 2026-06-11 (report last updated 2026-06-11); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163543
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Novo-Oxybutynin · DIN 02230394 · 5mg · tablet

General benefitMarketed · checked 2026-09-18
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Novo-Oxybutynin · DIN 02230394 Manufacturer: Novopharm Ltd.; listing date 1998-12-31 Health Canada: Marketed since 2015-07-27 · brand TEVA-OXYBUTYNIN · ATC G04BD04 OXYBUTYNIN · form Tablet · route Oral · ingredients OXYBUTYNIN CHLORIDE 5 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Novo-Oxybutynin: Formulary list price $0.0986/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0986 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49219 · Verify on the e-Formulary ↗ (DIN 02230394)

Source record
DIN 02230394: Novo-Oxybutynin Raw flags: sec3=Y Item: 120800033; group id 209; item number 0380; lccId None; manufacturer id NOP Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.0986; ministry $0.0986 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230394 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49219
Interchangeable products
Apo-Oxybutynin · DIN 02163543 · $0.0986 Ditropan · DIN 01924761 · not recorded PMS-Oxybutynin · DIN 02240550 · $0.0986
Shortage status: discontinued (2024-09-06, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230394
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Oxybutynin · DIN 02240550 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Oxybutynin · DIN 02240550 Manufacturer: Pharmascience Inc.; listing date 2000-07-17 Health Canada: Marketed since 1999-11-22 · brand PMS-OXYBUTYNIN · ATC G04BD04 OXYBUTYNIN · form Tablet · route Oral · ingredients OXYBUTYNIN CHLORIDE 5 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Oxybutynin: Formulary list price $0.0986/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0986 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64120 · Verify on the e-Formulary ↗ (DIN 02240550)

Source record
DIN 02240550: PMS-Oxybutynin Raw flags: sec3=Y Item: 120800033; group id 209; item number 0380; lccId None; manufacturer id PMS Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.0986; ministry $0.0986 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240550 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64120
Interchangeable products
Apo-Oxybutynin · DIN 02163543 · $0.0986 Ditropan · DIN 01924761 · not recorded Novo-Oxybutynin · DIN 02230394 · $0.0986
Shortage status: resolved shortage (ended 2018-08-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240550
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ditropan · DIN 01924753 · 1mg/mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-02-21 — choose a marketed DIN from the same-category list.Discontinued 2007-02-21 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-02-21 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2007-02-21 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ditropan · DIN 01924753 Manufacturer: Janssen-Ortho Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2007-02-21 · brand DITROPAN SYRUP 1MG/ML · ATC G04BD04 OXYBUTYNIN · form Syrup · route Oral · ingredients OXYBUTYNIN CHLORIDE 1 MG/ML · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Ditropan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14021 · Verify on the e-Formulary ↗ (DIN 01924753)

Source record
DIN 01924753: Ditropan Raw flags: notABenefit=Y, sec3=Y Item: 120800034; group id 209; item number 0379; lccId None; manufacturer id JNO Source form: O/L; strength: 1mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01924753 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14021
Interchangeable products
PMS-Oxybutynin · DIN 02223376 · $0.1249
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01924753
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2007-02-21 — choose a marketed DIN from the same-category list.

Ditropan · DIN 01924761 · 5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-08-04 — choose a marketed DIN from the same-category list.Discontinued 2006-08-04 · checked 2026-09-18
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-08-04 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2006-08-04 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ditropan · DIN 01924761 Manufacturer: Proctor & Gamble Pharmaceuticals Canada, Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2006-08-04 · brand DITROPAN TABLETS 5MG · ATC G04BD04 OXYBUTYNIN · form Tablet · route Oral · ingredients OXYBUTYNIN CHLORIDE 5 MG · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Ditropan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14030 · Verify on the e-Formulary ↗ (DIN 01924761)

Source record
DIN 01924761: Ditropan Raw flags: notABenefit=Y, sec3=Y Item: 120800033; group id 209; item number 0380; lccId None; manufacturer id PGP Source form: Tab; strength: 5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01924761 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14030
Interchangeable products
Apo-Oxybutynin · DIN 02163543 · $0.0986 Novo-Oxybutynin · DIN 02230394 · $0.0986 PMS-Oxybutynin · DIN 02240550 · $0.0986
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01924761
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2006-08-04 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (12:08 Parasympatholytic (Cholinergic Blocking) Agents) and how they are covered

Matched class: 12:08 Parasympatholytic (Cholinergic Blocking) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ACLIDINIUM BROMIDE, BENZTROPINE MESYLATE, ETHOPROPAZINE HCL, GLYCOPYRRONIUM BROMIDE, PROCYCLIDINE HCL, TIOTROPIUM BROMIDE MONOHYDRATE, UMECLIDINIUM Some products covered without a code (check the product listing): IPRATROPIUM BROMIDE, TRIHEXYPHENIDYL HCL 12:08 Parasympatholytic (Cholinergic Blocking) Agents

FLAVOXATE HCL

· 2 products · Listed, not a benefit · strengths: 200mg · Tab

ACLIDINIUM BROMIDE

· 1 products · General benefit · strengths: 400mcg/actuation · Pd Inh-60 Dose Pk

BENZTROPINE MESYLATE

· 1 products · General benefit · strengths: 1mg · Tab

ETHOPROPAZINE HCL

· 1 products · General benefit · strengths: 50mg · Tab

GLYCOPYRRONIUM BROMIDE

· 1 products · General benefit · strengths: 50mcg · Inh Pd-Cap

IPRATROPIUM BROMIDE

· 12 products · Listed, not a benefit (3), Limited Use, codes 256, 257, 258, 259 (3), Limited Use, codes 265, 266, 267, 268 (4), General benefit (2) · strengths: 250mcg/mL, 125mcg/mL, 20mcg/Metered Dose · Inh Sol-20mL Pk, Inh Sol-2mL UDV Pk, Inh-200 Dose Pk

PROCYCLIDINE HCL

· 1 products · General benefit · strengths: 2.5mg · Tab

TRIHEXYPHENIDYL HCL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 2mg, 5mg · Tab

HYOSCINE BUTYLBROMIDE

· 2 products · Limited Use, codes 481 · strengths: 10mg · Tab

IPRATROPIUM BROMIDE/SALBUTAMOL

· 3 products · Listed, not a benefit (1), Limited Use, codes 256, 257, 258, 259 (2) · strengths: 500mcg/2.5mg/2.5mL · Inh Sol-2.5mL Amp Pk

SCOPOLAMINE HYDROBROMIDE

· 4 products · Listed, not a benefit (2), Limited Use, codes 481 (2) · strengths: 0.4mg/mL, 0.6mg/mL · Inj Sol (Preservative Free)

TRIMEBUTINE MALEATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:08 and 5 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE APO-OXYBUTYNIN (oxybutynin chloride) is indicated for the relief of symptoms associated with voiding in patients with uninhibited neurogenic bladder and reflex neurogenic bladder (i.e. urgency, frequency, urinary leakage, urge incontinence, dysuria). Geriatrics (> 65 years of age): Clinical studies of oxybutynin chloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between healthy elderly and younger patients. Page 3 of 23 Pediatrics (< 5 years of age): The safety and effectiveness of oxybutynin chloride in pediatric patients under 5 years of age have not been established. https://pdf.hres.ca/dpd_pm/00064481.PDF PM date: January 24, 2022 Source product: APO-OXYBUTYNIN; DIN 02163543; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Oxybutynin · DIN 02163543 Shortage status: shortage reported ended 2026-06-11 (report last updated 2026-06-11); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163543

Check this DIN again

Novo-Oxybutynin · DIN 02230394 Shortage status: discontinued (2024-09-06, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230394

Check this DIN again

Other review policies

For Ditropan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026